Ignite Creation Date:
2025-12-24 @ 9:48 PM
Ignite Modification Date:
2025-12-29 @ 12:08 AM
Study NCT ID:
NCT01469832
Status:
COMPLETED
Last Update Posted:
2024-10-31
First Post:
2011-11-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000080362', 'term': 'Stargardt Disease'}, {'id': 'D012164', 'term': 'Retinal Diseases'}, {'id': 'D008268', 'term': 'Macular Degeneration'}], 'ancestors': [{'id': 'D015785', 'term': 'Eye Diseases, Hereditary'}, {'id': 'D005128', 'term': 'Eye Diseases'}, {'id': 'D012162', 'term': 'Retinal Degeneration'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 12}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2011-12-13', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-10', 'dispFirstSubmitDate': '2016-09-16', 'completionDateStruct': {'date': '2015-09-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-10-29', 'studyFirstSubmitDate': '2011-11-08', 'dispFirstSubmitQcDate': '2016-09-16', 'studyFirstSubmitQcDate': '2011-11-09', 'dispFirstPostDateStruct': {'date': '2016-09-23', 'type': 'ESTIMATED'}, 'lastUpdatePostDateStruct': {'date': '2024-10-31', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2011-11-10', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-09-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'safety and tolerance of transplantation', 'timeFrame': '12 months', 'description': 'The safety and tolerance of transplantation of hESC-derived MA09-hRPE will be considered safe and tolerated in the absence of: Any grade 2 NCI grading system)or greater adverse event related to the cell product.Any evidence that the cells are contaminated with an infectious agent, or have tumorigenic potential, Adverse Event and Serious Adverse Event assessment, Serial vital signs and Clinical laboratory tests Direct ophthalmological monitoring Monitoring of RPE cells acceptance/integrity/rejection Monitoring of local and systemic infection or tumorigenic cell transformation'}], 'secondaryOutcomes': [{'measure': 'Evidence of successful engraftment', 'timeFrame': '12 months', 'description': '•Evidence of successful engraftmentEvidence of successful engraftment will consist of:\n\n* Structural evidence (OCT imaging, fluorescein angiography, autofluorescence photography, slit-lamp examination with fundus photography) that cells have been implanted in the correct location\n* Electroretinographic evidence (mfERG) showing enhanced activity in the implant location'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['fundus flavimaculatus', 'Retinal Diseases', 'Macular Degeneration', 'SMD', 'juvenile macular dystrophy'], 'conditions': ["Stargardt's Macular Dystrophy"]}, 'referencesModule': {'references': [{'pmid': '22281388', 'type': 'BACKGROUND', 'citation': 'Schwartz SD, Hubschman JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, Mickunas E, Gay R, Klimanskaya I, Lanza R. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012 Feb 25;379(9817):713-20. doi: 10.1016/S0140-6736(12)60028-2. Epub 2012 Jan 24.'}, {'pmid': '25458728', 'type': 'BACKGROUND', 'citation': "Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, Hubschman JP, Davis JL, Heilwell G, Spirn M, Maguire J, Gay R, Bateman J, Ostrick RM, Morris D, Vincent M, Anglade E, Del Priore LV, Lanza R. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015 Feb 7;385(9967):509-16. doi: 10.1016/S0140-6736(14)61376-3. Epub 2014 Oct 15."}, {'pmid': '29884405', 'type': 'DERIVED', 'citation': 'Mehat MS, Sundaram V, Ripamonti C, Robson AG, Smith AJ, Borooah S, Robinson M, Rosenthal AN, Innes W, Weleber RG, Lee RWJ, Crossland M, Rubin GS, Dhillon B, Steel DHW, Anglade E, Lanza RP, Ali RR, Michaelides M, Bainbridge JWB. Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration. Ophthalmology. 2018 Nov;125(11):1765-1775. doi: 10.1016/j.ophtha.2018.04.037. Epub 2018 Jun 5.'}], 'seeAlsoLinks': [{'url': 'https://astellasclinicalstudyresults.com/patientStudySearch.aspx?RID=;;;7316-CL-0003', 'label': 'Link to results on the Astellas Clinical Study Results website.'}, {'url': 'https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217491&parentIdentifier=7316-CL-0003&attachmentIdentifier=f0a212f7-4d32-484f-a92f-26ff8c4d318a&fileName=7316-CL-0003_0006_Plain_language_summary.pdf&versionIdentifier=', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is:\n\nTo evaluate the safety and tolerability of RPE cellular therapy in patients with SMD .\n\nTo evaluate potential efficacy endpoints to be used in future studies RPE cellular therapy.', 'detailedDescription': "This study is a Phase I/II, open-label, non randomized, sequential, multi-center clinical trial. There will be 5 cohorts, the 4 low vision cohorts will contain 3 patients, the better vision cohort will contain 4 patients. The enrolled cohorts will be as follows:\n\nThree SMD patients- 50,000 MA09-hRPE cells transplanted\n\nThree SMD patients- 100,000 MA09-hRPE cells transplanted\n\nFour Better Vision SMD patients- 100,000 MA09-hRPE cells transplanted\n\nThree SMD patients- 150,000 MA09-hRPE cells transplanted\n\nThree SMD patients- 200,000 MA09-hRPE cells transplanted\n\nPatients will be enrolled sequentially, and within each cohort of 3 patients, each patient's clinical course over the first 6 weeks following cell transplantation will be reviewed by an independent (DSMB) before enrollment is opened for the next 2 patients. A full safety assessment of all 3 patients in each cohort will be made by the DSMB when the 3rd patient in each cohort completes 4 weeks of follow-up, and before the first patient in the next cohort receives a cell transplant. The exception is the better vision group where all patients may be enrolled once DSMB approval has been received.\n\nEach cohort will be enrolled sequentially in turn, with the exception of the better vision cohort which may be enrolled in parallel with the other cohorts.\n\nThe day of the cell implantation will be Day 0, and patients will remain in the study until the last visit at 12 months."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Adult male or female over 18 years of age. Clinical diagnosis of SMD If known, the patient"s genotype will be recorded in the medical history, if unknown, patient will allow for the submission of a sample for genotyping.\n\nIndependently verified clinical findings consistent with SMD. The visual acuity of the eye to receive the transplant will be no better than 20/400. The visual acuity of the eye in the better vision cohort to receive the transplant will be no better than 20/100.\n\nThe visual acuity of the eye that is not to receive the transplant will be no better than 20/400 for the worse vision patients and no worse than 20/100 for the better vision patients.\n\nElectrophysiological findings consistent with SMD . Medically suitable to undergo vitrectomy and subretinal injection. Medically suitable for general anaesthesia or waking sedation, if needed.\n\nMedically suitable for transplantation of an embryonic stem cell line:\n\n* Normal serum chemistry (sequential multi-channel analyzer 20 \\[SMA-20\\]) and hematology (complete blood count \\[CBC\\], prothrombin time \\[PT\\], and activated partial thromboplastin time \\[aPTT\\]) screening tests.\n* Negative urine screen for drugs of abuse.\n* Negative human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) serologies.\n* No history of malignancy, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin.\n* Negative cancer screening within previous 6 months:\n\ncomplete history \\& physical examination; dermatological screening exam for malignant lesions; negative fecal occult blood test negative chest roentgenogram (CXR); normal CBC \\& manual differential; negative urinalysis (U/A);normal thyroid exam and thyroid panel; if male, normal testicular examination; if over age 40, digital rectal examination (DRE) and prostate specific antigen (PSA); if female, normal pelvic examination with Papanicolaou smear; and if female, normal clinical breast exam and if 50 years of age or older, negative mammogram.\n\nIf female and of childbearing potential, willing to use an effective form of birth control during the study.\n\nIf male, willing to use barrier and spermicide contraception during the study. Willing to defer all future blood, blood component or tissue donation. Able to understand and willing to sign the informed consent.\n\nExclusion Criteria:\n\n* History of malignancy, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin.\n\nHistory of myocardial infarction in previous 12 months. History of diabetes mellitus. Any immunodeficiency. Any current immunosuppressive therapy other than intermittent or low dose corticosteroids.\n\nSerologic evidence of infection with Hepatitis B, Hepatitis C, or HIV. Current participation in any other clinical trial. Participation within previous 6 months in any clinical trial of a drug by ocular or systemic administration.\n\nAny other sight-threatening ocular disease. Any chronic ocular medications. Any history of retinal vascular disease (compromised blood-retinal barrier. Glaucoma. Uveitis or other intraocular inflammatory disease. Significant lens opacities or other media opacity. Ocular lens removal within previous 3 months'}, 'identificationModule': {'nctId': 'NCT01469832', 'briefTitle': "Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)", 'organization': {'class': 'INDUSTRY', 'fullName': 'Astellas Pharma Inc'}, 'officialTitle': "A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)", 'orgStudyIdInfo': {'id': '7316-CL-0003'}, 'secondaryIdInfos': [{'id': '2011-000054-34', 'type': 'EUDRACT_NUMBER'}, {'id': 'ACT hESC-RPE SMD 01 EU', 'type': 'OTHER', 'domain': 'Sponsor'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Subretinal injection of MA09-hRPE', 'description': '* Cohort 1 50,000 cells\n* Cohort 2 100,000 cells\n* Cohort 2a Better Vision 100,000 cells\n* Cohort 3 150,000 cells\n* Cohort 4 200,000 cells', 'interventionNames': ['Biological: MA09-hRPE']}], 'interventions': [{'name': 'MA09-hRPE', 'type': 'BIOLOGICAL', 'description': '* Cohort 1 50,000 cells\n* Cohort 2 100,000 cells\n* Cohort 2a Better Vision 100,000 cells\n* Cohort 3 150,000 cells\n* Cohort 4 200,000 cells', 'armGroupLabels': ['Subretinal injection of MA09-hRPE']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'EH1 3EG', 'city': 'Edinburgh', 'country': 'United Kingdom', 'facility': 'Lothian Health Board Headquarters at Waverley Gate', 'geoPoint': {'lat': 55.95206, 'lon': -3.19648}}, {'zip': 'EC1V2PD', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Moorefields Eye Hospital NHS Foundation Trust', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'NE7 7DN', 'city': 'Newcastle upon Tyne', 'country': 'United Kingdom', 'facility': 'Newcastle on Tyne NHS Foundation Trust', 'geoPoint': {'lat': 54.97328, 'lon': -1.61396}}], 'overallOfficials': [{'name': 'Medical Director', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Astellas Institute for Regenerative Medicine'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': "Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/."}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Astellas Institute for Regenerative Medicine', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}